Remimazolam for preventing new irregular heartbeat after bypass heart surgery
Tests remimazolam anesthesia in adults having heart bypass surgery to prevent new atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Remimazolam for Postoperative Atrial Fibrillation
Key facts
- Where
- Yangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50-70 who will have planned coronary artery bypass surgery at one hospital in China. It tests whether remimazolam during anesthesia lowers the chance of new atrial fibrillation after surgery.
- Age
- 50 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Planned (not emergency) coronary artery bypass grafting (CABG) surgery at the Yangzhou Institute Heart and Great Vessels, Affiliated Hospital of Yangzhou University, Yangzhou, China.
- Earlier treatment
- People who had chemotherapy or radiotherapy, or earlier chest or cardiovascular surgery, cannot join. People using diuretics before surgery cannot join.
Main reasons for not taking part
- Emergency surgery
- Any other type of cardiac surgery
- Irregular heartbeat from the upper heart chambers (supraventricular arrhythmia) before surgery
- Moderate or severe heart valve disease before surgery
- History of chemotherapy, radiotherapy, or chest or cardiovascular surgery
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT05891145, who can take part
Where in China
- The Affiliated Hospital of Yangzhou University.Yangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yangzhou University
- Trial code
- NCT05891145
- Record updated
- 6 June 2023
- Original description
Atrial fibrillation (AF) is the most common cardiac severe arrhythmia globally and is associated with an increased risk of mortality and morbidity, with a loss of 6.0 million disability-adjusted life-years worldwide in 2017, conferring 0.24% of total disability-adjusted life-years globally. Due to the absence of knowledge of AF pathogenesis, currently, available therapies do not prevent AF onset or progression in 85% of patients. Despite the identification of novel druggable targets that are involved in the pathogenesis of AF, the translation of these findings to clinical drug studies is limited.Read full original descriptionShow less
The Effect of Remimazolam on Postoperative New-onset Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting
Atrial fibrillation (AF) is the most common cardiac severe arrhythmia globally and is associated with an increased risk of mortality and morbidity, with a loss of 6.0 million disability-adjusted life-years worldwide in 2017, conferring 0.24% of total disability-adjusted life-years globally. Due to the absence of knowledge of AF pathogenesis, currently, available therapies do not prevent AF onset or progression in 85% of patients. Despite the identification of novel druggable targets that are involved in the pathogenesis of AF, the translation of these findings to clinical drug studies is limited.
Postoperative atrial fibrillation (POAF) is the most common type of secondary AF. The incidence of POAF after coronary artery bypass grafting (CABG) is approximately 30%. About 16% of patients developed POAF in cardiac surgery even with the international guideline recommended perioperative beta-blocker intervention.
Remimazolam is a newly approved benzodiazepine sedative indicated for the induction and maintenance of procedural sedation in adults, with significantly reduced sedation and recovery time. It was also found to be with an anti-inflammatory effect and therefore might have an impact on POAF since AF is closely related to the inflammatory response of myocardial tissue and inflammatory factors such as TNF-α. So, the RePAF trial intends to explore whether remimazolam application in induction and maintenance for general anesthesia during cardiac surgery can reduce the incidence of POAF in patients with CABG, and the effect on the postoperative plasma levels of inflammatory factors and stress factors.
Inclusion: 50-70 years old; BMI 18-28 kg/m2；; Selective CABG surgery will be performed at the Yangzhou Institute Heart and Great Vessels, the Affiliated Hospital of Yangzhou University, Yangzhou, China; Patients agree to participate in this study and sign the informed consent form.
Exclusion: Emergency surgery; diuretics usage before the surgery; with any other type of cardiac surgery; pre-operative supraventricular arrhythmia; with moderate or severe valve disease before surgery; with a history of chemotherapy or radiotherapy; with a history of thoracic or cardiovascular surgery.